Engineering Medicines To Improve Patient Care
Viridian Announces
Positive Initial
VRDN-001 Clinical Data
Substantial and rapid improvement in both signs and symptoms of TED at week 6 after two infusions of 10mg/kg VRDN-001
News Release Data Deck Webcast
Our Lead Programs
Our therapeutic programs harness groundbreaking clinical discoveries and proven technologies to craft best-in-class monoclonal antibodies.
VRDN-001
Learn MoreAn anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody in development for thyroid eye disease (TED)
VRDN-002
Learn MoreOur second generation product candidate for TED, incorporates half-life extension technology and is intended for subcutaneous administration
Treatments
Targeting
Patient Needs
We are dedicated to creating solutions for patients’ most pressing needs. Learn more about our initial programs for patients suffering from Thyroid Eye Disease.
Viridian Announces
Positive Initial
VRDN-001 Clinical Data
Substantial and rapid improvement in both signs and symptoms of TED at week 6 after two infusions of
10mg/kg VRDN-001
A New Path to Better Medicines
We have reimagined therapeutics research and development, accelerating the transformational benefits biotechnology can offer to patients suffering from serious diseases.
Learn MoreNovel Therapeutics Designed For Impact
Our pipeline of candidate therapeutics reflects a patient-centric model of innovation. We leverage proven biology and technology to efficiently craft medicines to meet the needs of patients and healthcare providers.